文章核心观点 - 文章讨论了在当前市场环境下，哪些模因股票（meme stocks）值得在下跌时买入，以期待未来的大幅上涨 [1][2][3][5][7] 模因股票的特性 - 模因股票的特点是基本面因素在投资决策中退居次要地位，主要依赖市场情绪和投机行为推动股价 [1] - 文章建议选择那些既有投机潜力又有较好基本面的股票，以避免大幅上涨后的深度回调 [1] 具体推荐的股票 Riot Platforms (RIOT) - Riot Platforms 是一家比特币矿工公司，目前股价被低估，未来增长潜力巨大 [3] - 公司过去12个月股价下跌15%，但仍有19%的自由流通股被做空 [3] - 公司拥有强劲的基本面，无债务，现金储备（包括数字资产价值）达13亿美元，为产能扩张提供充足空间 [3] - 公司计划在2024年底将产能从12.5EH/s增加到31.5EH/s，2027年进一步增加到100EH/s，预计将带来显著的收入和EBITDA增长 [3][4] Aurora Cannabis (ACB) - Aurora Cannabis 是一家大麻公司，预计在美国总统选举前后会有大量市场活动，特别是关于联邦层面的大麻合法化辩论 [5] - 公司股价在过去12个月内一直横盘整理，如果业务发展保持积极，可能会迎来大幅突破 [5] - 公司在2024财年第四季度实现了连续第六个季度的调整后EBITDA为正，并重申了在2024年12月实现正自由现金流的目标 [5] - 公司在德国有业务，预计在友好的监管环境下增长加速，澳大利亚也是一个有吸引力的市场 [6] Entera Bio (ENTX) - Entera Bio 是一家临床阶段的生物技术公司，专注于口服递送肽和其他治疗性蛋白质 [7] - 公司股价在4月份达到52周高点3.35美元后大幅回调至1.87美元，被视为买入机会 [7] - 公司最先进的产品EB613用于治疗高风险、绝经后骨质疏松症，市场潜力巨大，因为全球有2亿女性受此影响，且自2019年以来没有新的骨质疏松症疗法获批 [7] - 公司现金储备足以支撑到2025年第三季度，短期内没有因股权稀释导致的股价下跌风险 [8]

Cannabis Investing 2024 Here Are 3 Canadian Marijuana Stocks For YouThe cannabis sector has experienced a large amount of growth over the years. From just a few legal states and global regions to now over 50% of the USA has a legal cannabis market. Yet even with all this progress the industry continues to face an uphill battle. Cannabis operators around the United States are dealing with several conflicting concerns.One is federal reform and having laws passed in favor of small batches and legend growers. T ...

Aurora Cannabis Inc. (NASDAQ:ACB) Q4 2024 Earnings Conference Call June 20, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Matt Bottomley - Canaccord Eric Livshits - ATB Capital Markets John Zamparo - CIBC Pablo Zuanic - Zuanic Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Fourth Quarter 2024 Results Conference Call. All participants will be in a listen-only mode and a question- ...

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to loss of $1.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 161.11%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.20, delivering a surprise of -100%.Over the last four quarters, the co ...

Delivers Record Annual Adjusted EBITDA1 of $12.8 Million NASDAQ | TSX: ACB Q4 Represents the Sixth Consecutive Quarter of Positive Adjusted EBITDA1 Increased Total Quarterly Net Revenue 5% YoY to $67.4 Million, Global Medical Cannabis Net Revenue1 Grew by 20% YoY to $45.6 Million Ended the Fiscal Year with a Cash Position of ~$180 Million with Cannabis Business Debt-Free2 Re-Affirms Target of Reaching Positive Free Cash Flow1 by December 31, 2024 EDMONTON, AB, June 20, 2024 /PRNewswire/ - Aurora Cannabis ...

NASDAQ | TSX: ACB EDMONTON, AB, June 7, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets th ...

"We are thrilled to bring premium resin cartridges to the Australian market, a signal of our commitment to expanding patient access to an even greater variety of premium cannabis," said Kristin Viccars, Interim Managing Director, MedReleaf Australia. "Our products are designed with the highest standards of quality with safety in mind, and we are confident that Australian patients will value the unique experience our cartridges offer. We continue to look at new opportunities to expand our portfolio and patie ...

Short-squeeze moves can be ferocious and are perfect for investors seeking quick trading gains. With the possibility of a rate cut-induced rally, I am bullish on some short-squeeze stocks for the next few quarters.I am a long-term investor. However, I don’t shy away from taking trading positions in 5% to 10% of my fund allocation towards equities. When there are some clear short-squeeze opportunities, it makes sense to make 50% or 100% gains and invest the profits in long term bets. Of course, the short-squ ...

Going by the price action in some stocks in the recent past, it seems that the meme stock euphoria is at its early stage. Potential rate cuts to boost economic growth will likely be a perfect recipe for a full-fledged meme stock season. It’s, therefore, a good time to look at some short-squeeze stocks to buy for quick returns in the blink of an eye.I always prefer to keep expectations on a base-case scenario. Therefore, I expect a 50% rally in the short-squeeze stocks discussed. However, a 2x or 3x rally in ...

This beaten-down pot stock may have a lot of upside only if the U.S. marijuana market opens up for business.Thus far, 2024 has been an exceptional year for Aurora Cannabis (ACB) stock. Up more than 40%, it's been generating some impressive returns for investors. And recent developments involving rescheduling marijuana in the U.S. has gotten investors even more bullish about the stock and its long-term prospects.Could the Biden Administration's latest move, to reclassify marijuana as a Schedule III substance ...